ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

ClinicalTrials.gov ID: NCT06211036

Public ClinicalTrials.gov record NCT06211036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Study identification

NCT ID
NCT06211036
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
563 participants

Conditions and interventions

Interventions

  • Durvalumab Drug
  • Tarlatamab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 4, 2024
Primary completion
Jul 4, 2027
Completion
Sep 29, 2028
Last update posted
Dec 16, 2025

2024 – 2028

United States locations

U.S. sites
37
U.S. states
24
U.S. cities
35
Facility City State ZIP Site status
Infirmary Cancer Center Mobile Alabama 36607
University of Southern California Los Angeles California 90033
Yale New Haven Hospital New Haven Connecticut 06510
University Cancer and Blood Center LLC Athens Georgia 30607
Emory University Atlanta Georgia 30322
Northeast Georgia Medical Center Gainesville Georgia 30501
University of Illinois Chicago Chicago Illinois 60612
Franciscan Health Indianapolis Indianapolis Indiana 46237
Our Lady of the Lake Cancer Institute Baton Rouge Louisiana 70808
Dana-Farber Cancer Institute Boston Massachusetts 02215
Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan 49503
Mayo Clinic Rochester Minnesota 55905
Allina Health System dba Allina Health Cancer Institute Saint Paul Minnesota 55102
Oncology Hematology Associates Springfield Missouri 65807
Nebraska Cancer Specialists Omaha Nebraska 68130
Astera Cancer Care East Brunswick New Jersey 08816
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901
Montefiore Medical Center - Bronx The Bronx New York 10461
Duke University Durham North Carolina 27710
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
Oncology Hematology Care Incorporated Cincinnati Ohio 45242
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
The Ohio State University Columbus Ohio 43210
Oncology Associates of Oregon, PC Eugene Oregon 97401
Oregon Health and Science University Portland Oregon 97239
Allegheny Health Network Pittsburgh Pennsylvania 15212
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232
Medical University of South Carolina Charleston South Carolina 29425
Baptist Cancer Center Memphis Thoracic Memphis Tennessee 38120
Sarah Cannon Research Institute Nashville Tennessee 37203
Texas Oncology - Dallas Fort Worth Dallas Texas 75246
US Oncology Research Investigational Products Center Dallas Texas 75246
University of Texas MD Anderson Cancer Center Houston Texas 77030
Virginia Oncology Associates Newport News Virginia 23606
Virginia Commonwealth University Massey Cancer Center Richmond Virginia 23298
Swedish Cancer Institute Seattle Washington 98104
The Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 182 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06211036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2025 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06211036 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →